{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:50:54Z","timestamp":1791337854961,"version":"4.3.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T00:00:00Z","timestamp":1238544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T00:00:00Z","timestamp":1238544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T00:00:00Z","timestamp":1238544000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T00:00:00Z","timestamp":1238544000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T00:00:00Z","timestamp":1238544000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T00:00:00Z","timestamp":1238544000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T00:00:00Z","timestamp":1238544000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Sleep Medicine"],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.1016\/j.sleep.2008.04.004","type":"journal-article","created":{"date-parts":[[2008,8,27]],"date-time":"2008-08-27T05:25:56Z","timestamp":1219814756000},"page":"416-421","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Exacerbation of cataplexy following gradual withdrawal of antidepressants: Manifestation of probable protracted rebound cataplexy"],"prefix":"10.1016","volume":"10","author":[{"given":"Ruzica K.","family":"Ristanovic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl S.","family":"Hornfeldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chinglin","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.sleep.2008.04.004_bib1","first-page":"704","article-title":"Pharmacotherapy in narcolepsy","volume":"21","author":"Akimoto","year":"1960","journal-title":"Dis Nerv Syst"},{"key":"10.1016\/j.sleep.2008.04.004_bib2","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.smrv.2004.01.004","article-title":"Pharmacotherapy for cataplexy","volume":"8","author":"Houghton","year":"2004","journal-title":"Sleep Med Rev"},{"key":"10.1016\/j.sleep.2008.04.004_bib3","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/ana.10444","article-title":"The neurobiology, diagnosis and treatment of narcolepsy","volume":"53","author":"Scammell","year":"2003","journal-title":"Ann Neurol"},{"key":"10.1016\/j.sleep.2008.04.004_bib4","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0301-0082(96)00070-6","article-title":"Pharmacological aspects of human and canine narcolepsy","volume":"52","author":"Nishino","year":"1997","journal-title":"Prog Neurobiol"},{"issue":"Suppl. 1","key":"10.1016\/j.sleep.2008.04.004_bib5","first-page":"86","article-title":"The use of clomipramine as an REM sleep suppressant in narcolepsy","volume":"56","author":"Chen","year":"1980","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.sleep.2008.04.004_bib6","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1136\/pgmj.70.819.34","article-title":"A patient with coexisting narcolepsy and morbid jealousy showing favourable response to fluoxetine","volume":"70","author":"Wing","year":"1994","journal-title":"Postgrad Med J"},{"issue":"Suppl. 1","key":"10.1016\/j.sleep.2008.04.004_bib7","first-page":"217","article-title":"Venlafaxine in the treatment of the narcoleptic syndrome","volume":"5","author":"Smith","year":"1996","journal-title":"J Sleep Res"},{"issue":"1 Pt. 2","key":"10.1016\/j.sleep.2008.04.004_bib8","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1093\/sleep\/9.1.275","article-title":"Viloxazine hydrochloride in narcolepsy: a preliminary report","volume":"9","author":"Guilleminault","year":"1986","journal-title":"Sleep"},{"key":"10.1016\/j.sleep.2008.04.004_bib9","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1093\/sleep\/24.3.282","article-title":"Stimulant and anticataplectic effects of reboxetine in patients with narcolepsy: a pilot study","volume":"24","author":"Larrosa","year":"2001","journal-title":"Sleep"},{"key":"10.1016\/j.sleep.2008.04.004_bib10","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1517\/14656566.4.7.1165","article-title":"Atomoxetine: a selective noradrenaline reuptake inhibitor for the treatment of attention-deficit\/hyperactivity disorder","volume":"4","author":"Kratochvil","year":"2003","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.sleep.2008.04.004_bib11","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1600-0404.1976.tb07621.x","article-title":"Evaluation of short-term and long-term treatment of the narcolepsy syndrome with clomipramine hydrochloride","volume":"54","author":"Guilleminault","year":"1976","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.sleep.2008.04.004_bib12","first-page":"113","article-title":"Status cataplecticus induced by abrupt withdrawal of clomipramine","volume":"17","author":"Martinez-Rodriguez","year":"2002","journal-title":"Neurologia"},{"key":"10.1016\/j.sleep.2008.04.004_bib13","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(79)92495-4","article-title":"Clomipramine and clonazepam in cataplexy","volume":"2","author":"Parkes","year":"1979","journal-title":"Lancet"},{"key":"10.1016\/j.sleep.2008.04.004_bib14","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1136\/jnnp.43.2.171","article-title":"Fluvoxamine and clomipramine in the treatment of cataplexy","volume":"43","author":"Schachter","year":"1980","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.sleep.2008.04.004_bib15","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/sleep\/9.2.371","article-title":"Fluoxetine in the treatment of cataplexy","volume":"9","author":"Langdon","year":"1986","journal-title":"Sleep"},{"key":"10.1016\/j.sleep.2008.04.004_bib16","first-page":"246","article-title":"Rebound cataplexy, a complication of drug withdrawal in narcolepsy","volume":"17","author":"Scharf","year":"1988","journal-title":"Sleep Res"},{"key":"10.1016\/j.sleep.2008.04.004_bib17","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1212\/01.wnl.0000175978.61048.62","article-title":"Unusually prolonged rebound cataplexy after withdrawal of fluoxetine","volume":"65","author":"Poryazova","year":"2005","journal-title":"Neurology"},{"issue":"Suppl.","key":"10.1016\/j.sleep.2008.04.004_bib18","first-page":"A219","article-title":"Severity of rebound cataplexy is worse following the discontinuation of tricylic antidepressants (TCAs) than selective serotonin reuptake inhibitors (SSRIs)","volume":"29","author":"Ristanovic","year":"2006","journal-title":"Sleep"},{"key":"10.1016\/j.sleep.2008.04.004_bib19","doi-asserted-by":"crossref","unstructured":"Xyrem\u00ae International Study Group. Further evidence supporting the use of sodium oxybate for the treatment of cataplexy: a double-blind, placebo-controlled study in 228 patients. Sleep Med 2005;6:415\u201321.","DOI":"10.1016\/j.sleep.2005.03.010"},{"key":"10.1016\/j.sleep.2008.04.004_bib20","unstructured":"Xyrem\u00ae International Study Group. A double-blind, placebo-controlled, study demonstrates sodium oxybate is effective for the treatment of excessive daytime sleepiness in narcolepsy. J Clin Sleep Med 2005;1:289\u201395."},{"key":"10.1016\/j.sleep.2008.04.004_bib21","unstructured":"American Academy of Sleep Medicine. International classification of sleep disorders, revised: diagnostic and coding manual. Chicago, IL: American Academy of Sleep Medicine; 2001."},{"key":"10.1016\/j.sleep.2008.04.004_bib22","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1093\/sleep\/17.3.265","article-title":"Stability of cataplexy over several months-information for the design of therapeutic trials","volume":"17","author":"Gelb","year":"1994","journal-title":"Sleep"},{"key":"10.1016\/j.sleep.2008.04.004_bib23","doi-asserted-by":"crossref","first-page":"426","DOI":"10.2165\/00023210-199605060-00003","article-title":"Narcolepsy. Current drug treatment options","volume":"5","author":"Hublin","year":"1996","journal-title":"CNS Drugs"},{"key":"10.1016\/j.sleep.2008.04.004_bib24","first-page":"CD003724","article-title":"Antidepressant drugs for narcolepsy","volume":"3","author":"Vignatelli","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.sleep.2008.04.004_bib25","unstructured":"US Xyrem\u00ae Multicenter Study Group. A randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep 2002;25:42\u20139."},{"key":"10.1016\/j.sleep.2008.04.004_bib26","doi-asserted-by":"crossref","unstructured":"US Xyrem\u00ae Multicenter Study Group. Sodium oxybate demonstrates long-term efficacy for the treatment of cataplexy in patients with narcolepsy. Sleep Med 2004;5:119\u201323.","DOI":"10.1016\/j.sleep.2003.11.002"},{"key":"10.1016\/j.sleep.2008.04.004_bib27","doi-asserted-by":"crossref","unstructured":"US Xyrem\u00ae Multicenter Study Group. The abrupt cessation of therapeutically administered sodium oxybate (GHB) does not cause withdrawal symptoms. J Toxicol Clin Toxicol 2003;41:131\u20135.","DOI":"10.1081\/CLT-120019128"}],"container-title":["Sleep Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1389945708001159?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1389945708001159?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T15:05:24Z","timestamp":1761404724000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1389945708001159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,4]]}},"alternative-id":["S1389945708001159"],"URL":"https:\/\/doi.org\/10.1016\/j.sleep.2008.04.004","relation":{},"ISSN":["1389-9457"],"issn-type":[{"value":"1389-9457","type":"print"}],"subject":[],"published":{"date-parts":[[2009,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exacerbation of cataplexy following gradual withdrawal of antidepressants: Manifestation of probable protracted rebound cataplexy","name":"articletitle","label":"Article Title"},{"value":"Sleep Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.sleep.2008.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}